The purpose of this study is to evaluate the difference in clinical outcomes for patients with metastatic spine disease treated with a whole versus partial vertebral body contouring approach. A retrospective study was performed for the clinical outcomes of 154 metastatic lesions to the spine in 117 patients treated with stereotactic body radiation therapy (SBRT) using the Cyberknife TM Robotic Radiosurgery System. Each patient was treated with a single session of radiotherapy using either a whole (WB) or a partial vertebral body contour approach (PB). The primary endpoint was re-treatment rate and the secondary endpoints were pain status, neurologic status, toxicity, tumor control, and survival. The WB group had a lower re-treatment rate (11% (WB) vs. 18.6% (PB), p 5 0.285). Prior surgery status (β 5 1.953, OR 5 7.052, p  0.001) was correlated to the re-treatment rate. Trends for local tumor control were distinct for both treatment groups (X 2 5 3.380, p-value 5 0.066). Treatment group (β 5 21.1017, OR 5 0.362, p 5 0.029) was significantly correlated to the local tumor control rate. The 2-year survival was 25.7% in WB and 20.9% in PB (p 5 0.741). Contouring the whole vertebral body for stereotactic body radiation therapy treatment of metastatic spinal lesions shows potential benefits by reducing the risk of recurrence, improving symptomatic relief and providing improved local tumor control.
Introduction
Bony metastases are a common occurrence in cancer patients affecting approximately 36-40% of patients with a cancer diagnosis (1, 2) . The most common malignancies that spread to the bone include breast cancer, lung cancer, and prostate cancer (2). The vertebral column represents the most common skeletal site of involvement (3) (4) (5) . The range of symptoms from spinal metastases is wide, with some lesions being asymptomatic while others compress the spinal cord leading to severe pain and neurologic dysfunction.
The goals for management of metastatic spine disease are to control the tumor locally, provide symptomatic pain relief, and stabilize or reverse the progression of neurologic deficits. Current treatment options for bony metastatic disease of the spine include surgical decompression and stabilization with or without adjuvant radiation therapy given in a single and multi-session course (5). Radiation may be delivered by several methods including 3D conformational radiation therapy Technology in Cancer Research & Treatment, Volume 11, Number 2, April 2012 (3D-CRT), intensity-modulated radiation therapy (IMRT), and stereotactic body radiotherapy (SBRT) . SBRT involves the delivery of a highly conformal single, high dose of radiation using a stereotactic approach (6). This technique has been used to treat patients with solitary spine lesions with no spinal instability who are not good surgical candidates or have a short life expectancy (7) . In addition, SBRT is a useful technique for the re-treatment of previously irradiated spine metastases that exhibit evidence of progression or progressive/recurrent pain (8) . Multiple studies have shown SBRT is efficacious in providing adequate local tumor control and symptomatic relief for patients with spinal metastatic disease (7, (9) (10) (11) (12) (13) .
Although SBRT for spinal metastases has been shown to be effective, several aspects of treatment including fractionation schedules and contouring methods have not been standardized and show considerable variation between treating physicians (14) . It is possible that the volumes of vertebral body contoured, prescription dose, fractionation scheme, and overall dosimetry could affect the outcomes in patients with spinal metastases treated with SBRT. With this concept in mind, the authors conducted a retrospective study to compare the clinical outcomes of patients treated with whole vertebral body SBRT compared to partial vertebral body SBRT.
Materials and Methods
A retrospective review of 154 metastatic lesions to the spine in 117 patients treated was performed. This study was conducted under an approved Institutional Review Boardproposal. Patients eligible for this study had metastatic spine disease with a primary diagnosis of lung, breast, multiple myeloma, colorectal, or thyroid cancer. Patients treated with or without previous external beam irradiation to the spine were included in the study. Patients with less than 3 months life expectancy, spinal instability, or prior surgical intervention for the lesion under examination were excluded from the study. Tumors were treated with single session SBRT treatment. Patients were followed post-treatment at 1 to 2 weeks, 2 to 4 weeks, 2 to 3 months, 4 to 6 months, 7 to 12 months and 12 to 24 months. Data collection included initial and periodic assessment of several categorical factors (improve, increase, stable, etc.) including pain, neurologic status, tumor control and adverse events. The primary endpoint for this study was need for retreatment and the secondary endpoints were local control, pain, neurologic status, tumor control, toxicity and overall survival. Local control was assessed by radiographic validation with either computed tomography (CT) or magnetic resonance imaging (MRI) post-treatment. Toxicity was assessed using the National Cancer Institute's Common Toxicity Criteria version 3 (CTCAE v.3).
Contour Treatment Plan
A chart review examining the treatment plan for each lesion was performed to assess whether each lesion was treated using either a partial vertebral body contour approach (PB group) or a whole vertebral body contour approach (WB group). The criteria for lesions treated by either contour approach was developed and confirmed by two radiation oncologists with extensive experience treating spine metastases using SBRT. To be designated within the PB group, the 80% isodose line should delineate only a portion of the vertebral body (in any plane) with obvious asymmetry implying only a portion of the vertebral body was intentionally treated. Several examples are displayed in Figures 1 and 2 . Contour plans for a pedicle or posterior spinous process were also considered to be a partial vertebral body contour approach as well. To be designated within the WB group, the 80% isodose line should significantly delineate the complete vertebral body (in all planes) with obvious symmetry suggesting an intentional treatment of the entire vertebral body. Several examples are displayed in Figures 1 and 2. Lesions that were treated primarily for paraspinal masses were excluded from the study. Sacral lesions that were treated without designation for the exact anatomical level were excluded from the study. Histopathology did not influence contouring of the GTV.
Pre-Treatment Assessment
Each patient was evaluated by a multi-disciplinary team consisting of a neurosurgeon, radiation oncologist, imaging specialist, and, when indicated, a pain specialist and social worker. Pretreatment CT, MRI, and prior radiation records were used in formulating a specific treatment plan. In general, patients were simulated in the supine, head-first position for Cyberknife TM Robotic Radiosurgery [Accuray, Inc, Sunnyvale, CA]. In a subset of patients treated before 2004, including patients in both the WB and PB cohorts, gold fiducial markers were placed in or around the spine to enable near real-time tracking. After 2004, some patients were treated with the Cyberknife TM tracking software, Xsight® Spine Tracking System that eliminates the need for surgical implantation of fiducials. The Xsight® system registers unique non-rigid and bony anatomical landmarks to track, detect, and correct for movement of the spine in real-time during treatment. The details of this frameless radiosurgical system have been previously described (15, 16) .
Radiation Therapy Treatment Planning
In each case, the radiosurgical treatment plan was designed based on tumor geometry, proximity to the spinal cord, and location. The planning tumor volume (PTV) was defined as equal to gross tumor volume (GTV). The spinal cord, cauda equina, nerve roots, and bowel were contoured as organs at risk (OARs) and critical structures. Treatment planning was conducted on the CT scan; however, a fused image of CT and MR images was consulted whenever further visualization was necessary. An inverse treatment planning method along with a linear optimization algorithm were employed. The target volume was designated to include either the GTV and the entire vertebral body (WB group) or only the GTV (PB group) at each spinal level.
Treatment Delivery
The process of treatment delivery has been described in detail previously (15, 16) . Briefly, the patients were positioned on the Cyberknife TM treatment couch in a supine position with the appropriate immobilization aides, Aquaplast mask for cervical lesions or conformable alpha cradle for thoracic, lumbar, or sacral lesions. Patients were offered a mild sedative when considered helpful by the treating physician.
Patient Evaluations
Study coordinators extracted the data from medical charts and other sources (e.g., CT and MR images/reports) and exported them into a database for biostatistical analysis. Outcomes were assessed based on pain, neurological symptoms, local tumor control, toxicity, and need for re-treatment.
Pain: Pain relief was evaluated after radiotherapy as relatively improved/stable/worsened compared to baseline pain level. Data were collected at 1 to 2 weeks; and at months 2 to 3, 4 to 6, 7 to 12, and 12 to 24 after treatment. Pain was assessed at each follow up visit using the Brief Pain Inventory (BPI) developed by the Pain Research Group of the WHO Collaborating Centre for Symptom Evaluation in Cancer Care. Neurological Assessment: Neurological status was evaluated for all patients who presented with neurologic deficits at baseline and during follow-up. Neurologic deficits, including paresis and parasthesias, attributable to the treated lesions were assessed and followed. The outcome was classified as improved/stable/worsened relative to the severity of the condition at baseline. Data were collected at 1 to 2 weeks and at months 2 to 3, 4 to 6, 7 to 12, and 12 to 24 after treatment.
Local Control: Local tumor control was evaluated based on the CT/MR images comparing before and after radiotherapy treatment. Tumor growth less than 25% was classified as "tumor control." Toxicity: Adverse events were assessed using the National Cancer Institute's Common Toxicity Criteria, version 3 (CTCAE v.3). Information on the type of the adverse event including start date, stop date, treatments received, relationship to the SBRT treatment, outcome, need for hospitalization, and seriousness was collected.
Re-treatment:
Rates of retreatment were assessed based on whether the patient had received multiple sessions of Cyberknife SBRT to the same or overlapping lesion.
Statistical Considerations
Data analysis was performed with SPSS Version 17.0 (IBM Corp., Somers, NY). Chi-square tests were carried out for testing the difference between the primary endpoint, re-treatment rates. Kaplan-Meier curves were calculated from the survival data to determine median and mean survival (17). Kaplan-Meier curves were applied for analysis of other categorical outcomes including pain, neurologic status, and local tumor control. Log Rank (Mantel-Cox) analyses were performed to assess the statistical significance of the . A Z-test of proportions was calculated to compare statistical differences between the toxicity rates for the two groups. An alpha 5 0.05 significance level was chosen; a p-value less than 0.05 was considered statistically significant. Binary logistic regression (BLR) analysis was performed on survival, local tumor control and re-treatment rates to determine, if any, the relative impact of multiple independent factors on each outcome. First round BLR analysis implemented a forward step-wise method with an entry parameter of 0.05 and removal parameter of 0.10. Second round BLR analysis was conducted using the inclusion variables from the forward step-wise regression. Independent variables used in the logistic regression analyses were age, sex (categorical), histology (categorical), tumor volume, previous radiation (categorical), previous surgery (categorical), radiation dose, total radiation dose and treatment type (WB vs. PB).
Results

Patient Characteristics
The retrospective study cohort consisted of 117 patients with 154 lesions with a median follow-up of 282 days for both groups. The WB group consisted of 81 patients with 109 lesions. The PB group consisted of 36 patients with 45 lesions. The WB group (n 5 109) had 54 men (50%) and 55 women (50%) while the PB group (n 5 45) had 17 men (38%) and 28 women (62%). The median age for the WB group was 57 years (range 31-82 years) and the median age for the PB group was 62 years (range 31-85 years). A summary of patient characteristics can be found in Table I . With respect to location of the lesion, all lesions were extradural and within the bone. Lesion histologies were relatively well-balanced between the two groups with the four most prevalent types for both groups being renal, breast, lung and melanoma. Previous treatment with external beam radiation therapy and surgical intervention were comparable in both groups. The primary indication for treatment in the WB and PB groups was pain (97% vs. 100%, respectively). The second most frequent indication for treatment was the presence of neurologic deficits (6% (WB) vs. 13% (PB)) followed by spinal cord compression (5.5% (WB) vs. 2.3% (PB)) and bone erosion, respectively. The thoracic vertebrae were the most common location for the lesion in both groups (55% (WB) vs. 44% (PB)) followed by the lumbar vertebrae (33% in both groups). All other sites treated are included on Table I . The median follow-up was 282 days for the entire cohort. The median follow-up was 9.4 months (297 days) for the PB group and 9.1 months (273 days) for the PB group.
Treatment Characteristics
Patients in both groups were treated with a single session of radiation therapy. Treatment characteristics are displayed in Table II . The median prescription dose was the same for both groups. Both groups had a median prescription dose of 16.0 Gy (range 12.0-20.0 Gy). The prescribed isodose line for both groups was 80%. The median maximum dose to the spinal cord in the WB group was 10.0 Gy (range 8.0-15.2 Gy) and the median for the PB group was 9.6 Gy (range 3.7-14.8 Gy).
Pain
Pain was the primary indication for treatment in at least 97% of the patients. The pain response is depicted in Figure 3 . The trend for improvement of pain following radiotherapy is similar for both groups. By the end of the 24-month follow-up period, there was an overall reduction in pain for 97.2% (WB) and 100% (PB) of the cases. Both groups had symptomatic pain improvement in at least 25% of the patients by the 28 th day post-treatment and in at least 50% of the patients by the 35 th day post-treatment. In the PB group, there was symptomatic pain improvement in 75% of the patients after 45 days post-treatment (vs. 55 days for the WB group). Several patients in the WB group did have longer response times with respect to pain remission, but the overall trend was similar. Log rank (Mantel-Cox) analysis was performed which yielded a chi-square value of 0.746 and p-value of 0.338.
Neurologic Symptoms
Neurologic symptoms were the primary indication for treatment in 8% of the patients overall. The response in neurologic symptoms following radiation therapy is shown in Figure 4 . Overall, the PB group experienced more relief of neurologic symptoms in comparison to the WB group. The PB group had a 14% reduction in neurologic symptoms 2 years following radiotherapy (vs. 5.5% in the WB group). Log rank (Mantel-Cox) analysis was performed which yielded a chi-square value of 3.059 and a p-value of 0.080 that was not statistically significant (p  0.05). Although there was a quantitative difference between the two groups with respect to neurologic symptom improvement, the trend of the curves is visibly similar; improvements in neurologic symptoms were only observed within the first 60 days.
Local Tumor Control
Local tumor control was considered an important outcome because it could potentially affect re-treatment rates. In the cohort, 80 (52.6%) cases had imaging studies to assess for local tumor control following treatment. Figure 5 shows the local tumor control rate following radiotherapy for both groups. The PB group showed relatively poorer local tumor control in comparison to the WB group. The PB group experienced local tumor progression in 10% of the cases after 55 days (vs. 150 days in the WB group) and in 20% (interpolated) of the cases after 146 days (vs. 400 days in the WB group). After 2 years following SBRT, the PB group experienced local tumor progression in 34.9% of the cases (vs. 21.1% in the WB group). Log rank (Mantel-Cox) analysis was performed which yielded a chi-square value of 3.380 and a trend towards significance (p-value of 0.066). Although there was a relative difference in local tumor control, both groups did show similar trends in response to SBRT. Table III shows the results from logistic regression analysis of the local tumor control rate. Age (p 5 0.04), sex (p 5 0.047), and treatment type (p 5 0.029) were significantly correlated to the local tumor control rate. Gender (β 5 0.923, OR 5 2.158) was positively correlated to the local tumor control rate while age (β 5 20.056, OR 5 0.945) and treatment group (β 5 21.1017, OR 5 0.362) were negatively correlated. Lesions treated in the WB group reduced the odds for developing tumor progression.
Toxicity Assessment
Treatment-related adverse events were recorded and analyzed for the entire cohort. The rate of toxicity did not significantly differ between the two groups. The WB group (n 5 10) had a 9.67% toxicity rate. There were 5 episodes of nausea, 2 episodes of vomiting, 2 episodes of dermatitis and 1 episode of diarrhea. Of the 10 episodes, 9 were rated Grade 1 toxicity and one was rated Grade 2 toxicity. 6 adverse events were transiently acute while the other 4 adverse events were transiently late. The PB group (n 5 1) had a 2.22% toxicity rate. The one adverse event was a late and transient episode of nausea and was rated grade 3 toxicity. Although the toxicity rate was higher in the WB group, there was no statistical significant difference between the two groups (p 5 0.098). Pain flare is also commonly reported but, in general, occurred within 24-48 hours and would then resolve within a similar timeframe. Since patients had phone follow-ups at 2 weeks and more commonly face to face 1 month post treatment, these would not be obvious at that time point.
Re-Treatment
The need for additional radiotherapy was assessed after the delivery of the primary session of radiation therapy. The re-treatment rate for the entire cohort was 13.2%. When we compare both groups directly, we observe that the WB group had a lower re-treatment rate (11% (WB) vs. 18.6% (PB), p 5 0.285). Table IV displays the results of the logistic regression analysis of the re-treatment rate. The status of prior surgery (β 5 1.953, OR 5 7.052) was positively correlated to the re-treatment rate as well.
Survival
The overall median survival time for the entire cohort was 10.7 months. The median survival for the WB group is 10.5 months (vs. 13.0 months for the PB group). The overall 2-year survival was 25.7% in WB and 20.9% in PB (p 5 0.741) ( Figure 6 ). Table V shows the results of the logistic regression analysis of the survival rate. Only the radiation treatment dose (p 5 0.007) was significantly correlated to the survival rate (β 5 0.005, OR 5 1.004).
Discussion
Stereotactic body radiotherapy plays an important role in the multi-disciplinary care of patients with spine metastasis. Patients with solitary lesions in the vertebrae with no spinal instability, no rapid development of neurologic deficits, and those who have a short life expectancy should be considered for treatment with SBRT (7). Several studies have demonstrated the efficacy of radiosurgery in the reduction pain and the ability to locally control metastatic spine disease (9-13). Although SBRT has become widely accepted as a viable therapeutic option in selected cases, there remains significant debate amongst clinicians with respect to a single or multi-session fractionation schedule and treatment planning protocols. Ryu et al. showed that patients treated with single fraction SBRT (mean 10-16 Gy) for solitary lesions in the spine showed a reduction of pain in 85% of the group and tumor control in 95% of group after one year (19). Gerszten et al. studied metastatic melanoma in the spine with single session radiosurgery and observed pain improvement in 96% of the group and long-term tumor control in 75% of the group (12). Gerszten et al. studied metastatic renal cell carcinoma in the spine with single session radiosurgery and observed an overall reduction of pain in 87% of the group and tumor control in 87.5% of the group (13). Our retrospective study demonstrates a similar trend for outcomes in comparison to the previously mentioned studies. In both the WB and PB group, there was an overall reduction in pain for 97.2% and 100% of the cases, respectively. Local tumor control (i.e. no further local tumor progression) for the WB group was 79% while it was 65% in the PB group.
Although our findings are relatively comparable to the other studies previously mentioned, the data does also suggest there are potential inherent differences between the two treatment methods (WB vs. PB). We hypothesized that there would be a significant difference in the re-treatment rate, but not in the secondary endpoints (pain, neurologic symptoms, tumor control and survival) of the study. The findings suggested a mixed picture that supported aspects of this initial hypothesis while rejecting others. Re-treatment rates were different between the two groups (11% (WB) vs. 18.6% (PB), p 5 0.285), however the results were not statistically significant which may be an indication of the size of this study. Logistic regression analysis for re-treatment rate compared by treatment types also did not reveal significant differences. Lesions treated with prior surgical intervention (β 5 1.953, OR 5 7.052, p  0.001) were positively correlated with the re-treatment rate. This may simply be a surrogate marker for patients with more extensive and aggressive disease, or could suggest that prior surgery may spread microscopic disease. This finding does not negate the important role of surgery in appropriately selected patients with spinal metastases. This correlation, however, does highlight the need to develop better and more specific techniques for contouring the GTV and PTV for lesions that have been previously treated with surgical intervention.
The survival rate is an important secondary endpoint for this study because we can determine the relative impact for each treatment type. The rates were not quantitatively different (20.9% (PB) vs. 25.7% (WB)) in this study (p 5 0.741). Given the local nature of both treatments in a setting where all patients have metastatic disease, we did not expect to find a difference in overall survival. Logistic regression showed that there was, however, a correlation between the survival rate and the radiation treatment dose (β 5 0.005, OR 5 1.004, p 5 0.007). This analysis suggested that increasing the prescribed treatment dose (µ 5 16.0 Gy) may increase the odds for survival and highlights the importance of aggressive treatment when deciding upon a prescription dose. Determining the prescribed dose to optimize treatment while minimizing the toxicity remains a challenge in spinal SBRT. Sahgal et al. previously mentioned in their review of the literature that dose heterogeneity between institutions continues to remain a problem and must be resolved to provide better treatment protocols for all institutions (20).
Local tumor control was assessed following initial radiotherapy with either CT or MRI. Figure 5 shows that the trends were relatively distinct for both treatment groups (p 5 0.066). The regression analysis suggested that younger individuals and those treated with the whole vertebral body contour approach had decreased odds for tumor progression. The negative relationship between the treatment type and the local tumor control rate is important because tumor progression may inevitably develop the need for further radiotherapy (i.e. re-treatment).
As noted previously, the WB group did show better overall local tumor control. Contouring the whole vertebral body may deliver a more effective radiation dose to the vertebrae to treat more microscopic disease at the margins of the tumor volume when the lesions are solitary and unilateral. Gerszten et al. suggested that they could have potentially prevented recurrence following SBRT if they had contoured more generous margins to include more "normal appearing" vertebral body (11). They noted that a portion of the recurrent disease was located at the margin of the treatment volume suggesting that they may not have adequately treated those areas due to dose drop-off proximal to the margin. Their rationale and findings support the need to contour more generous margins trending towards whole vertebral body contours (11). Chang et al. suggested that vertebral metastases with no prior irradiation can be treated with liberal margins in order to prevent invasion into the epidural space. They also made the suggestion to consider treating the pedicles and posterior vertebral elements to in order to prevent invasion into those structures as well (21). Both recommendations provide support, again, for a trend towards contouring the whole vertebral body for metastatic spinal disease. Relative reduction in re-treatment rate and improvement in the local tumor control rate and pain response suggest that contouring the whole vertebral body would help to reduce healthcare costs while benefiting the patients' quality of life.
Re-irradiation to the vertebral column is another consideration that requires careful attention. This situation is frequently a challenging problem because it requires meticulous reconstruction of prior doses, including those of adjacent structures to avoid dose escalation to the vertebral column and spinal cord, which could otherwise lead to pathologic fractures and myelopathy (22, 23) . Determining the optimal dose for re-treatment of recurrent metastatic spinal disease can be complicated by a previous treatment because the dose to the spinal cord and vertebral body is cumulative and SBRT doses are typically large in relation to dose tolerance for both organs (24). Sahgal et al. showed that the planning tumor volume (PTV) for re-irradiation of recurrent disease in vertebral body deteriorated 15% to 37% when compared to vertebral body not previously irradiated (25). This reduction in the PTV suggests the treatment for re-irradiation may be sup-optimal resulting in an increased risk of recurrence or persistent symptoms.
A third and final approach that can be considered for treating asymmetric spinal lesions in a vertebral body is the Simultaneous Integrated Boost (SIB) technique. SIB radiotherapy Figure 6 : Survival following SBRT for both groups. There is no qualitative or quantitative difference in the survivorship for the two treatment groups. This appears to be the first study to evaluate these two approaches to treating vertebral spinal metastases using SBRT. As such, we realize that more data points must to be collected in order to better evaluate the efficacy of contouring the whole vertebral body and the confounding variables. Chao et al. recently performed a recursive partition analysis (RPA) of SBRT for spinal metastases looking at different factors including histology, gender, age, Karnofsky performance status (KPS), control of primary, extraosseous metastases, time from primary diagnosis (TPD), dose of SBRT, extent of disease, upfront or salvage treatment, presence of paraspinal extension, and previous surgery (30). They showed that patients with higher KPS scores and favourable histologies had better prognosis for overall survival. Further studies should include KPS scores because this has been shown to be predictive in other tumors treated with radiation therapy (31).
Our study used re-treatment rates as the primary endpoint for analysis because this was an indirect reflection of several important factors that must be considered including success of treatment for relief of pain and cost effectiveness. In future studies, we suggest that pain relief be the primary endpoint for analysis as palliation is the primary indication for treating spinal metastases. Additionally, narcotics and corticosteroids use should be collected in order to better assess the true efficacy of SBRT for palliation.
Our institutional policy on the use of SBRT versus IMRT for palliation for bone metastases after prior radiation therapy is based on the higher degree of immobilization, accuracy and efficacy based on our clinical experience of well over 700 patients treated to date. It is certainly important that future studies include a more comprehensive assessment of toxicity, efficacy and cost-effectiveness to better understand the role of SBRT in the treatment of cancer patients with bone metastases. Additionally, dosimetric parameters including the dose to the spinal cord need to be included in order to validate our protocol and provide important information to other radiation oncologists. Based on our experience and the findings of this study, we continue to recommend contouring the whole vertebral body for solitary lesions (unilateral and bilateral) in the vertebrae for metastatic spine disease. Contouring the whole vertebral body has shown a trend towards reducing re-treatment rates and improving both pain control and local control. Additionally, contouring an asymmetric portion of the vertebral body could further complicate dosimetric planning for re-irradiation of metastatic spinal disease.
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